Switching to Tenecteplase for Stroke Thrombolysis
Stroke2021Vol. 52(10), pp. e590–e593
Citations Over TimeTop 10% of 2021 papers
Abstract
Following stakeholder endorsement, a region-wide switch from alteplase to tenecteplase was successfully implemented. We found evidence of benefit and no evidence of harm.
Related Papers
- → Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: Insights from the TETRIS registry(2022)39 cited
- → The Changing Landscape of Intravenous Thrombolysis for Acute Ischaemic Stroke(2024)7 cited
- → Tenecteplase utility in acute ischemic stroke patients: A clinical review of current evidence(2018)12 cited
- → Tenecteplase for Intravenous Thrombolysis of Ischemic Stroke: A Single MRI-based Comprehensive Stroke Center Experience(2022)
- → OUTCOME OF INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE IN ACUTE ISCHEMIC STROKE.(2022)